首页> 外文期刊>Cell transplantation >Indiscernible Benefit of Double-Unit Umbilical Cord Blood Transplantation in Children: A Single-Center Experience From Hong Kong
【24h】

Indiscernible Benefit of Double-Unit Umbilical Cord Blood Transplantation in Children: A Single-Center Experience From Hong Kong

机译:儿童双单元脐带血移植的益处不可忽视:来自香港的单中心经验

获取原文
获取原文并翻译 | 示例
       

摘要

Double-unit umbilical cord blood (DU-UCB) may extend the use of UCB transplantation and improve clinical outcomes. Data in the literature show that single-unit dominance happened in a vast majority of recipients, and the mechanism is unknown. We examined the clinical relevance and engraftment kinetics of DU-UCB transplant in 65 consecutive children who underwent unrelated single-unit (n=25) and double-unit (n=40) UCB transplantation for various hematological malignancies (n=45) and nonmalignant disorders (n=20). Our result showed no discernible benefit to children receiving double-unit transplant over those receiving single-unit transplant when the total nucleated cell (TNC) doses are >= 2.5 x 10(7)/kg, in terms of the hastening of the engraftment of neutrophils and platelets, reduction of nonengraftment, disease recurrence, early mortality, and graft-versus-host disease, despite significantly higher numbers of TNCs in double units. Further analyses demonstrated that the phenomena were not associated with underlying disease, duration of UCB storage, postthaw viability, HLA disparity, ABO incompatibility, gender, or doses of TNCs, CD34(+) cells, CD3(+) cells, or colony-forming units. Engrafting units in DU-UCB transplants were notably associated with higher CD34(+) cell dose. Chimerism studies demonstrated that single-unit dominance started before neutrophil engraftment in DU-UCB transplants. Data from the study suggested no advantage of infusing double-unit UCB, if an adequately dosed single-unit UCB is available. Successful prediction of the dominant graft would optimize algorithms of UCB selection and maximize the long-term engraftment of chosen units.
机译:双单位脐带血(DU-UCB)可能会扩展UCB移植的使用并改善临床效果。文献中的数据表明,绝大多数接收者都发生了单单位优势,其机制尚不清楚。我们研究了连续65例连续,不相关的单单位(n = 25)和双单位(n = 40)UCB移植的儿童在各种血液系统恶性肿瘤(n = 45)和非恶性肿瘤中DU-UCB移植的临床相关性和植入动力学疾病(n = 20)。我们的结果表明,当总成核细胞(TNC)剂量> = 2.5 x 10(7)/ kg时,与接受单单位移植的儿童相比,接受单单位移植的儿童没有明显的益处,这有助于加快移植的时间。中性粒细胞和血小板,减少非植入,疾病复发,早期死亡率和移植物抗宿主病,尽管双单位的TNC数量明显增加。进一步的分析表明,该现象与基础疾病,UCB储存时间,解冻后活力,HLA差异,ABO不相容性,性别或TNC剂量,CD34(+)细胞,CD3(+)细胞或集落形成无关。单位。 DU-UCB移植中的植入单位与较高的CD34(+)细胞剂量显着相关。嵌合论研究表明,在DU-UCB移植物中,嗜中性粒细胞植入之前,单单位优势开始。来自研究的数据表明,如果有足够剂量的单单位UCB,则输注双单位UCB没有优势。优势移植物的成功预测将优化UCB选择算法并最大化所选单位的长期移植物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号